Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2025 | YoY |
|---|---|---|
| Revenue | 23.99K | - |
| Gross profit | 0 | 100.00% |
| Net profit | -313.88K | 90.63% |
| EBITDA | -335.87K | 89.94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €892.76K |
Number of shares | 893.22K |
52-week high/low | €1.00 - €0.70 |
| Dividends | No |
Beta | 0.87 |
P/E ratio | -2.42 |
PEG ratio | -0.02 |
P/B ratio | 381.48 |
P/S ratio | 32.38 |
Company profile
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
| Name | EPIGENOMICS AG NA ON KONV Aktie |
| CEO | Jason Wouhra |
| Headquarters | Heidelberg,
be Germany |
| Website | |
| IPO | 12/31/2010 |
| Employees | 3 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | EPGNF |
XETRA | ECX.DE |
Frankfurt | ECX.F |
Düsseldorf | ECX.DU |
Hamburg | ECX.HM |
London | 0QXH.L |
München | ECX.MU |
